Search the Newsreel

Corcept CDO William Guyer sells $418,561 in common stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc., sold 3,700 shares of common stock for $418,561 on August 4, 2026, while also acquiring 3,700 shares by exercising stock options. This sale, conducted under a pre-arranged 10b5-1 plan, follows a significant 210% year-to-date surge …

Form 8K Corteva Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Corteva Inc. on August 6th. The content is brief and primarily serves as a notification of this corporate filing, with no additional details provided within the article itself. It includes various financial market data …

Why Corteva (CTVA) Raised EPS Guidance After Weaker Q2 Results And What That Really Signals

Corteva (CTVA) recently reported weaker Q2 2026 results with declining sales and net income but raised its full-year operating EPS guidance to US$3.60–US$3.80, signaling management's confidence in strong execution. This move, despite ongoing pricing pressure and competition in Crop Protection, repositions Corteva’s investment narrative, …

Corteva Inc. stock underperforms Thursday when compared to competitors

Corteva Inc. shares fell 2.30% on Thursday, closing at $76.86, despite a two-day winning streak being broken. This underperformance occurred on a tough trading day where the S&P 500 Index also declined by 0.18% and the Dow Jones Industrial Average fell by 0.85%. The …

Corteva Announces Private Exchange Offers and Consent Solicitations for EIDP's 2.300% Senior Notes Due 2030, 5.125% Senior Notes Due 2032 and 4.800% Senior Notes Due 2033

INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announced today that Vylor Inc., a Delaware corporation and its wholly owned subsidiary ("Vylor"), has commenced private offers to exchange (with respect to each series, an "Exchange Offer" and together, the "Exchange Offers") any …

Eligible noteholders may exchange EIDP debt for equal Vylor notes by Aug. 19

Corteva (NYSE: CTVA) has initiated private exchange offers for outstanding senior notes of its subsidiary EIDP, totaling $1.6 billion, in preparation for the separation of its seed business into a new entity, Vylor. Eligible noteholders who tender their EIDP notes by August 19, 2026, …

Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks

Corcept Therapeutics (CORT) stock has seen significant returns over the past five years, but its current valuation suggests it's not an obvious bargain. While broader metrics show the stock leaning towards expensive, a tailored Price/Sales (P/S) ratio indicates it may be undervalued, especially after …

Escorts Kubota sees mid-single digit tractor growth, plans ₹900 cr capex

We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings

Corcept Therapeutics (NASDAQ:CORT) recently reported lackluster earnings, but its stock price rose due to underlying positive factors. The company shows a strong accrual ratio of -0.15, indicating free cash flow significantly exceeding statutory profit, and benefited from an unusual tax credit of US$29 million. …

Corcept Therapeutics' (NASDAQ:CORT) Anemic Earnings Might Be Worse Than You Think

This article analyzes Corcept Therapeutics' recent financial performance, highlighting concerns about its declining profit margins and low shareholder returns despite revenue growth. The company's reliance on a single drug, Korlym, and increased R&D and selling expenses are identified as key factors contributing to its …

Cooper Investors PTY Ltd. Makes New $2.69 Million Investment in Corteva, Inc. $CTVA

Cooper Investors PTY Ltd. has made a new investment of

Raised Guidance Lifts Corcept to 52-Week High

Its second-quarter fiscal 2026 earnings report showed record revenue of $256.1 million (a 32% year-over-year rise), net income of $43 million (a 22.9% gain), $545 million in cash and investments, and raised 2026 revenue guidance of up to $1.2 billion. It's no wonder CORT …

Corteva, Inc. (NYSE: CTVA) director acquires 412.9081 deferred stock units

Corteva, Inc. director Christopher J. Policinski acquired 412.9081 deferred stock units on July 31, 2026, as part of the Stock Accumulation and Deferred Compensation Plan for Directors. This transaction, based on a reference price of $78.71 per share, increased his total direct holdings to …

Corteva (CTVA) director defers cash pay into stock units at $78.71

Corteva, Inc. director Janet Plaut Giesselman acquired 98.4627 stock units on July 31, 2026, by deferring cash compensation into common stock at a price of $78.71 per unit. Her direct holdings in the company now total 20,247.7383 stock units, including shares obtained through dividend …

CORT (NASDAQ: CORT) insider schedules 20,000-share option-related sale

Corcept Therapeutics (NASDAQ: CORT) has filed a Form 144 indicating a planned sale of 20,000 shares of common stock by insider William Guyer, valued at $2,256,000. This sale, scheduled for August 4, 2026, is related to a stock option exercise. Guyer has made similar …

Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation

Corcept Therapeutics (CORT) has seen its stock reach new all-time highs, with shares up over 50% in the past year, driven by strong fundamentals and bullish technical indicators. Despite its high valuation and mixed analyst sentiment, the company is projected to see significant growth …

ADM, Corteva Raise 2026 Profit Forecasts on Strong Processing and Seed Demand Outlooks

Archer-Daniels-Midland (ADM) and Corteva have both raised their 2026 profit forecasts due to strong oilseed processing outlooks and robust demand in key crop markets, particularly in the United States. ADM's revised forecast is attributed to increased farmer selling of corn and soybeans following a …

Why Corcept Therapeutics (CORT) Is Up 19.8% After Boosting 2026 Revenue Guidance And Earnings

Corcept Therapeutics (CORT) saw its stock rise by 19.8% after reporting strong second-quarter 2026 net income of US$42.99 million and raising its full-year 2026 revenue guidance to between US$1.1 billion and US$1.2 billion. This upward revision reflects management's confidence in its business momentum, despite …

Form 144 CORCEPT THERAPEUTICS INC For: 3 August By Investing.com

This article announces the filing of Form 144 by Corcept Therapeutics Inc. for August 3rd. It is a brief, direct notification published by Investing.com, likely indicating an insider's intent to sell restricted stock. The publication features standard stock market data, indices, and news headlines …

CORCEPT THERAPEUTICS INC SEC Filing (Aug 3, 2026)

This article reports on a Form 144 SEC filing by CORCEPT THERAPEUTICS INC (CORT) dated August 3, 2026. The filing indicates a proposed sale of securities, specifically 1540 shares of common stock with an aggregate market value of $175,806.00, acquired through option exercises. The …

A Look at Corteva Inc (CTVA) After 3.4% Decline -- GF Value $66.

Corteva Inc (CTVA) shares recently declined by 3.4%, bringing its price to $76.04. This price is 14.2% above its GF Value™ of $66.61, indicating the stock is "Modestly Overvalued" according to GuruFocus. Despite an above-average GF Score™ of 77/100, its P/E ratio is significantly …

UBS Group Issues Positive Forecast for Corteva (NYSE:CTVA) Stock Price

UBS Group has raised its price target for Corteva (NYSE:CTVA) from $86.00 to $89.00, while maintaining a "neutral" rating, indicating a potential 17.07% upside. This follows other positive analyst revisions from firms like Goldman Sachs and Deutsche Bank. Corteva also reported better-than-expected Q2 earnings, …

BMO raises Corteva stock price target to $100 on EBITDA outlook

BMO Capital has increased its price target for Corteva Inc. (NYSE:CTVA) to $100 from $95, maintaining an Outperform rating, due to an improved EBITDA outlook for 2027. The firm raised its 2027 EBITDA estimate to $4.5 billion, citing opportunities around an improved agricultural dynamic …

UBS Adjusts Price Target on Corteva to $89 From $86, Maintains Neutral Rating

UBS has adjusted its price target for Corteva (CTVA) to $89, up from $86, while maintaining a Neutral rating on the stock. This update reflects a change in the analyst's valuation, though the overall investment recommendation remains unchanged. The article also notes other recent …

Pacer Advisors Inc. Decreases Stake in Corteva, Inc. $CTVA

Pacer Advisors Inc. reduced its holdings in Corteva, Inc. (NYSE:CTVA) by 2.7% in the first quarter, selling 64,588 shares but still owning 2,289,146 shares valued at $191.62 million. Despite this, other institutional investors have recently increased their stakes in Corteva. The company announced a …

Escorts Kubota gains after July tractor sales climb 22% YoY

Escorts Kubota consolidated net profit declines 72.38% in the June 2026 quarter

Escorts Kubota Q1 Results: Earnings call recording uploaded

Q1 results: DLF, Ireda, Escorts Kubota, Jindal Stainless, 85 more on Aug 3

Escorts Kubota Q1 Results: Revenue growth of 28% but margins struggle

Escorts Kubota Q1FY27: Revenue jumps 28% Y-o-Y, profit at ₹386 crore

HC Wainwright Has Positive Estimate for CORT Q3 Earnings

Earnings call transcript: Escorts Kubota posts strong q1 2027 growth as shares rise

Corteva Raised Guidance and Still Dropped 12%. Is the Selloff Overdone?

Corteva, Inc. (CTVA) saw its stock drop nearly 12% despite beating earnings and raising its full-year outlook, primarily due to a revenue miss in its second quarter, particularly in Crop Protection. The market's anxiety also stems from the upcoming separation of the company into …

Q1 results this week: LIC, SBI, Nykaa, Bharti Airtel, BSE, MCX, Marico, Lupin, Biocon, Escorts Kubota and more

Corteva Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.25 Sh Revenue Breakdown – BMFBOVESPA:C1TV34 – TradingView

This article provides a revenue breakdown for Corteva Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.25 Sh (C1TV34) on the BMFBOVESPA. The main revenue contribution came from the United States, reporting 46.20 billion BRL last year, slightly up from 42.41 billion BRL the previous …